Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

The previous edition of the consensus guidelines of the International Workshop on Chronic
Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by …

Background Randomized trials of venetoclax plus anti-CD20 antibodies as first-line
treatment in fit patients (ie, those with a low burden of coexisting conditions) with advanced …

Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …

CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged≤ 70 years
with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort …

We previously reported durable responses in relapsed or refractory (R/R) chronic
lymphocytic leukemia (CLL) patients treated with CD19-targeted chimeric antigen receptor …

PURPOSE The CLL14 study has established one-year fixed-duration treatment of
venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic …

PURPOSE The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by
targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis …

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine …

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially
different manifestations of the same disease that are similarly managed. A number of …